Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...

HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy, HKEY-AIRxTM1.0 designed to address one of the most ...

The Drug Information Association (DIA) today announced the launch of DIA ASCENT, a new global platform designed to support early-stage biotechnology drug development innovation, along with its ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern ...

Chinese drugmaker Qilu Pharmaceutical will be responsible for developing metabolic disease drug candidates from Insilico Medicine under a contract with a total value that "approaches" $120 million, ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has granted orphan drug ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Edesa Biotech, Inc. has announced its financial results for the first half of 2025, highlighting a $15 million equity financing aimed at advancing its vitiligo drug candidate, EB06, an anti-CXCL10 ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...